Literature DB >> 10876986

On-site testing of saliva and sweat with Drugwipe and determination of concentrations of drugs of abuse in saliva, plasma and urine of suspected users.

N Samyn1, C van Haeren.   

Abstract

Potential drug users participated voluntarily in a Belgian study on the usefulness of the non-instrumental immunoassay Drugwipe (Securetec, Germany) for the screening of cocaine, opiates, amphetamine and cannabinoids in saliva and sweat. If one of the screening assays (urine, oral fluid, sweat) showed a positive result, blood and saliva were collected. The on-site Drugwipe results were correlated with the Drugwipe results for saliva in the laboratory and with the GC/MS results of the corresponding saliva, plasma and urine samples and pharmacological effects at the time of sampling. The Drugwipe assay proved to be sufficiently sensitive for the detection of recent cocaine (n = 6) and amphetamine (n = 15) abuse, whether the device was wiped on the tongue or on the surface of the body, or when a saliva sample was applied to the wiping part. In five of the six potential cocaine users, the saliva concentrations of cocaine exceeded 1,000 ng/ml. In the amphetamine group, the saliva concentrations of amphetamine, MDMA or both were high (> 1,000 ng/ml) in 13 subjects. For cocaine and amphetamine, the positive scores for Drugwipe matched the GC/MS results for the three body fluids. Recent heroin abuse (n = 5) could be demonstrated to some extent with Drugwipe on samples from the tongue but only the two subjects with the highest saliva concentrations of MAM (> 500 ng/ml) and morphine (> 500 ng/ml) were positive. If the legal cut-off value for driving under the influence of opiates in Belgium (20 ng/ml of free morphine in plasma) was taken into account, only three subjects would have been legally positive. For cannabinoids (n = 15), false negatives and even some false positives were observed. Saliva can be considered as a useful analytical matrix for the detection of drugs of abuse after recent abuse when analysed with GC/MS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10876986     DOI: 10.1007/s004140050287

Source DB:  PubMed          Journal:  Int J Legal Med        ISSN: 0937-9827            Impact factor:   2.686


  20 in total

1.  Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration.

Authors:  Garry Milman; Allan J Barnes; David M Schwope; Eugene W Schwilke; Robert S Goodwin; Deana L Kelly; David A Gorelick; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2011-06-03       Impact factor: 4.142

Review 2.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

Review 3.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

4.  Biological markers of drug use in the club setting.

Authors:  Brenda A Miller; Debra Furr-Holden; Mark B Johnson; Harold Holder; Robert Voas; Carolyn Keagy
Journal:  J Stud Alcohol Drugs       Date:  2009-03       Impact factor: 2.582

5.  Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration.

Authors:  Dayong Lee; Ryan Vandrey; Garry Milman; Mateus Bergamaschi; Damodara R Mendu; Jeannie A Murray; Allan J Barnes; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-07-06       Impact factor: 4.142

6.  Performance evaluation of the DrugWipe® 5/5+ on-site oral fluid screening device.

Authors:  Anna Pehrsson; Tom Blencowe; Kari Vimpari; Antti Impinen; Teemu Gunnar; Pirjo Lillsunde
Journal:  Int J Legal Med       Date:  2010-07-23       Impact factor: 2.686

7.  Predicting drug use at electronic music dance events: self-reports and biological measurement.

Authors:  Mark B Johnson; Robert A Voas; Brenda A Miller; Harold D Holder
Journal:  Eval Rev       Date:  2009-04-07

8.  Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration.

Authors:  Nathalie A Desrosiers; Allan J Barnes; Rebecca L Hartman; Karl B Scheidweiler; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-03-08       Impact factor: 4.142

Review 9.  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.

Authors:  Rafael de la Torre; Magí Farré; Mónica Navarro; Roberta Pacifici; Piergiorgio Zuccaro; Simona Pichini
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 10.  Current knowledge on cannabinoids in oral fluid.

Authors:  Dayong Lee; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2013-08-25       Impact factor: 3.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.